BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 2021; 27(12): 1117-1131 [PMID: 33828389 DOI: 10.3748/wjg.v27.i12.1117] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Whiteley D, Speakman E, Elliott L, Davidson K, Hamilton E, Jarvis H, Quinn M, Flowers P. Provider-related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis. J Viral Hepat 2021;28:528-37. [PMID: 33215781 DOI: 10.1111/jvh.13443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
6 Magri MC, Manchiero C, Dantas BP, da Silva Nunes AK, Figueiredo GM, Barone AA, Tengan FM. Hepatitis E virus seroprevalence in patients with chronic hepatitis C at a university hospital in Brazil. Future Virology 2020;15:791-9. [DOI: 10.2217/fvl-2020-0042] [Reference Citation Analysis]
7 Huang X, Glessner JT, Huang J, Zhou D, March ME, Wang H, Xia Q, Hakonarson H, Li J. Discovery of Novel Host Molecular Factors Underlying HBV/HCV Infection. Front Cell Dev Biol 2021;9:690882. [PMID: 34458256 DOI: 10.3389/fcell.2021.690882] [Reference Citation Analysis]
8 Chuaypen N, Khlaiphuengsin A, Prasoppokakorn T, Susantitaphong P, Prasithsirikul W, Avihingsanon A, Tangkijvanich P, Praditpornsilpa K. Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07074-2] [Reference Citation Analysis]
9 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A–E. Adv Ther. [DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
11 Martini F, Champagne E. The Contribution of Human Herpes Viruses to γδ T Cell Mobilisation in Co-Infections. Viruses 2021;13:2372. [PMID: 34960641 DOI: 10.3390/v13122372] [Reference Citation Analysis]
12 de Brito RJVC, da Silva LF, Santos MB, de Moura PMMF, de Souza CDF, do Carmo RF. A time series analysis of detection and mortality of hepatitis C in Brazil, 2008–2018. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07063-5] [Reference Citation Analysis]
13 Shoukry NH, Walker CM. T cell responses during HBV and HCV infections: similar but not quite the same? Curr Opin Virol 2021;51:80-6. [PMID: 34619514 DOI: 10.1016/j.coviro.2021.08.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Ann Transl Med 2021;9:624. [PMID: 33987322 DOI: 10.21037/atm-20-6901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Safaev K, Parpieva N, Liverko I, Yuldashev S, Dumchev K, Gadoev J, Korotych O, Harries AD. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013-2018. Int J Environ Res Public Health 2021;18:4663. [PMID: 33925705 DOI: 10.3390/ijerph18094663] [Reference Citation Analysis]
16 Balagopal A, Thio CL. When viruses collide: hepatitis B virus reactivation after hepatitis C treatment. J Clin Invest 2020;130:2823-6. [PMID: 32420916 DOI: 10.1172/JCI137477] [Reference Citation Analysis]
17 Barik S. Molecular Interactions between Pathogens and the Circadian Clock. Int J Mol Sci 2019;20:E5824. [PMID: 31756974 DOI: 10.3390/ijms20235824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Goodman S, Zahn M, Bruckner T, Boden-Albala B, Lakon CM. Measuring Hazards of Undetectable Viral Load among Hepatitis C Antibody Positive Residents of a Large Southern California County. Health Serv Res Manag Epidemiol 2021;8:23333928211066181. [PMID: 34926722 DOI: 10.1177/23333928211066181] [Reference Citation Analysis]
19 da Silva CB, Vieira DA, de Melo LF, Chagas ALS, Gomes AD, Faria Jr CLL, Teixeira R, de Magalhães Queiroz DM, Rocha GA, Soares MMS, Bezerra JMT, Silva LD. Interleukin-6-174G/C polymorphism is associated with a decreased risk of type 2 diabetes in patients with chronic hepatitis C virus. World J Hepatol 2020; 12(4): 137-148 [PMID: 32685106 DOI: 10.4254/wjh.v12.i4.137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Chang ML, Chen WT, Hu JH, Chen SC, Gu PW, Chien RN. Altering retinol binding protein 4 levels in hepatitis C: Inflammation and steatosis matter. Virulence 2020;11:1501-11. [PMID: 33135589 DOI: 10.1080/21505594.2020.1838742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Barili V, Vecchi A, Rossi M, Montali I, Tiezzi C, Penna A, Laccabue D, Missale G, Fisicaro P, Boni C. Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. Cells 2021;10:2563. [PMID: 34685543 DOI: 10.3390/cells10102563] [Reference Citation Analysis]
22 Yang X, Tang Y, Xu D, Zhang G, Xu P, Tang H, Pang L. Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Virol J 2021;18:156. [PMID: 34315488 DOI: 10.1186/s12985-021-01625-w] [Reference Citation Analysis]
23 Huang SC, Cheng PN, Liu CH, Yang HC, Su TH, Tseng TC, Chen PJ, Kao JH, Liu CJ. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. J Formos Med Assoc 2021:S0929-6646(21)00424-1. [PMID: 34538552 DOI: 10.1016/j.jfma.2021.09.002] [Reference Citation Analysis]
24 Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol 2021; 27(1): 19-36 [PMID: 33505148 DOI: 10.3748/wjg.v27.i1.19] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Gebert LFR, Law M, MacRae IJ. A structured RNA motif locks Argonaute2:miR-122 onto the 5' end of the HCV genome. Nat Commun 2021;12:6836. [PMID: 34824224 DOI: 10.1038/s41467-021-27177-9] [Reference Citation Analysis]
26 Wang H, Zhang Y, Zhou J, Li M, Chen Y, Liu Y, Liu H, Ding P, Liang C, Zhu X, Zhang Y, Xin C, Zhang G, Wang A. Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick. Front Cell Infect Microbiol 2022;12:816238. [DOI: 10.3389/fcimb.2022.816238] [Reference Citation Analysis]
27 Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract 2021;16:52. [PMID: 34384494 DOI: 10.1186/s13722-021-00260-8] [Reference Citation Analysis]
28 Chang ML, Hu JH, Yen CH, Chen KH, Kuo CJ, Lin MS, Lee CH, Chen SC, Chien RN. Evolution of ferritin levels in hepatitis C patients treated with antivirals. Sci Rep. 2020;10:19744. [PMID: 33184464 DOI: 10.1038/s41598-020-76871-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Talebi A, Kargar M. Hepatoprotective effects of metformin in hepatitis C virus-infected adolescents with beta thalassaemia major. Int J Clin Pract 2021;75:e14951. [PMID: 34965654 DOI: 10.1111/ijcp.14951] [Reference Citation Analysis]
30 Qian X, Xu C, Wu B, Tang H, Zhao P, Qi Z. SNORD126 Promotes Hepatitis C Virus Infection by Upregulating Claudin-1 via Activation of PI3K-AKT Signaling Pathway. Front Microbiol 2020;11:565590. [PMID: 33042070 DOI: 10.3389/fmicb.2020.565590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, Ferstl P, Schulz M, Peiffer KH, Queck A, Sauerbruch T, Brol MJ, Rohde G, Sanchez C, Moreau R, Arroyo V, Zeuzem S, Welsch C, Trebicka J. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur 2022;12:100240. [PMID: 34901909 DOI: 10.1016/j.lanepe.2021.100240] [Reference Citation Analysis]
32 Chang ML, Yang Z, Yang SS. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. Int J Mol Sci 2020;21:E8308. [PMID: 33167521 DOI: 10.3390/ijms21218308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Reference Citation Analysis]
34 Dröse S, Øvrehus ALH, Holm DK, Madsen LW, Mössner BK, Søholm J, Hansen JF, Røge BT, Christensen PB. A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project. BMC Infect Dis 2022;22:202. [PMID: 35232372 DOI: 10.1186/s12879-022-07196-7] [Reference Citation Analysis]
35 Ferreira AR, Ramos B, Nunes A, Ribeiro D. Hepatitis C Virus: Evading the Intracellular Innate Immunity. J Clin Med 2020;9:E790. [PMID: 32183176 DOI: 10.3390/jcm9030790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
36 Shmeleva EV, Colucci F. Maternal natural killer cells at the intersection between reproduction and mucosal immunity. Mucosal Immunol 2021;14:991-1005. [PMID: 33903735 DOI: 10.1038/s41385-020-00374-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Taniki N, Nakamoto N, Chu PS, Ichikawa M, Teratani T, Kanai T. Th17 cells in the liver: balancing autoimmunity and pathogen defense. Semin Immunopathol 2022. [PMID: 35211777 DOI: 10.1007/s00281-022-00917-9] [Reference Citation Analysis]
38 Fu Z, Cai W, Shao J, Xue H, Ge Z, Fan H, Dong C, Wang C, Zhang J, Shen C, Zhang Y, Huang P, Yue M. Genetic Variants in TNFSF4 and TNFSF8 Are Associated With the Risk of HCV Infection Among Chinese High-Risk Population. Front Genet 2021;12:630310. [PMID: 33841497 DOI: 10.3389/fgene.2021.630310] [Reference Citation Analysis]
39 Alzahrani N, Wu MJ, Shanmugam S, Yi M. Delayed by Design: Role of Suboptimal Signal Peptidase Processing of Viral Structural Protein Precursors in Flaviviridae Virus Assembly. Viruses 2020;12:E1090. [PMID: 32993149 DOI: 10.3390/v12101090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Zhou QH, Wu FT, Pang LT, Zhang TB, Chen Z. Role of γδT cells in liver diseases and its relationship with intestinal microbiota. World J Gastroenterol 2020; 26(20): 2559-2569 [PMID: 32523311 DOI: 10.3748/wjg.v26.i20.2559] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol 2021;56:158-67. [PMID: 33219410 DOI: 10.1007/s00535-020-01748-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Chang ML, Chang SW, Chen SC, Chien RN, Hsu CL, Chang MY, Fann CSJ. Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals. Viruses 2021;13:464. [PMID: 33799903 DOI: 10.3390/v13030464] [Reference Citation Analysis]
43 Kudrina I, Puzhko S, Filion KB, Gore G, Paraskevopoulos E, Windle S, Martel MO, Eisenberg MJ. Effectiveness of interventions for prevention of common infections in people who use opioids: a protocol for a systematic review of systematic reviews. Syst Rev 2021;10:298. [PMID: 34782008 DOI: 10.1186/s13643-021-01852-w] [Reference Citation Analysis]
44 Dengu F, Abbas SH, Ebeling G, Nasralla D. Normothermic Machine Perfusion (NMP) of the Liver as a Platform for Therapeutic Interventions during Ex-Vivo Liver Preservation: A Review. J Clin Med. 2020;9. [PMID: 32272760 DOI: 10.3390/jcm9041046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
45 Kemming J, Thimme R, Neumann-Haefelin C. Adaptive Immune Response against Hepatitis C Virus. Int J Mol Sci 2020;21:E5644. [PMID: 32781731 DOI: 10.3390/ijms21165644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
46 Piecha F, Gänßler JM, Ozga AK, Wehmeyer MH, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse AW, Schulze Zur Wiesch J. Treatment and re-treatment results of HCV patients in the DAA era. PLoS One 2020;15:e0232773. [PMID: 32369527 DOI: 10.1371/journal.pone.0232773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
47 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
48 Chen Y, Lin J, Zhao Y, Ma X, Yi H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J Zhejiang Univ Sci B 2021;22:609-32. [PMID: 34414698 DOI: 10.1631/jzus.B2000808] [Reference Citation Analysis]
49 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Reference Citation Analysis]
50 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
51 Reinecke B, Frericks N, Lauber C, Dinkelborg K, Matthaei A, Vondran FWR, Behrendt P, Haid S, Brown RJP, Pietschmann T. The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. J Virol 2022;:e0199521. [PMID: 35297672 DOI: 10.1128/jvi.01995-21] [Reference Citation Analysis]
52 Sidorkiewicz M. Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites 2021;11:273. [PMID: 33925362 DOI: 10.3390/metabo11050273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Gao Y, Nepal N, Jin SZ. Toll-like receptors and hepatitis C virus infection. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00155-7. [PMID: 34419367 DOI: 10.1016/j.hbpd.2021.07.011] [Reference Citation Analysis]
54 Di Stasio D, Lucchese A, Romano A, Elio Adinolfi L, Serpico R, Marrone A. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. Clin Oral Investig 2022. [PMID: 35477818 DOI: 10.1007/s00784-022-04507-9] [Reference Citation Analysis]
55 Chang ML, Lin YS, Chang MY, Hsu CL, Chien RN, Fann CS. Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study. Virulence 2021;12:270-80. [PMID: 33446046 DOI: 10.1080/21505594.2020.1870080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Oliveira AIN, Malta FM, Zitelli PMY, Salles APM, Gomes-Gouvea MS, Nastri ACS, Pinho JRR, Carrilho FJ, Oliveira CP, Mendes-Corrêa MC, Pessoa MG, Mazo DF. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C. BMC Gastroenterol 2021;21:81. [PMID: 33622266 DOI: 10.1186/s12876-021-01654-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
58 Moradifard S, Sharifi Z, Arabkhazaeli A, Ghasemi F. Evaluating serum levels of miR-181a and miR-let7a in HCV infected Iranian patients compared with healthy individuals. Gene Reports 2021;22:101001. [DOI: 10.1016/j.genrep.2020.101001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Kawada N. High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. JGH Open 2020;4:964-9. [PMID: 33102771 DOI: 10.1002/jgh3.12376] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Virseda-Berdices A, Brochado-Kith O, Díez C, Hontañon V, Berenguer J, González-García J, Rojo D, Fernández-Rodríguez A, Ibañez-Samaniego L, Llop-Herrera E, Olveira A, Perez-Latorre L, Barbas C, Rava M, Resino S, Jiménez-Sousa MA. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis. J Antimicrob Chemother 2021:dkab444. [PMID: 34888660 DOI: 10.1093/jac/dkab444] [Reference Citation Analysis]
61 Lyu H, Tang H, Liang Y, Huang S, Wang Y, Huang W, Zhou Y. Alcohol Consumption and Risk of Liver Fibrosis in People Living With HIV: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:841314. [DOI: 10.3389/fimmu.2022.841314] [Reference Citation Analysis]
62 Khlaiphuengsin A, Chuaypen N, Sodsai P, Reantragoon R, Han WM, Avihingsanon A, Tangkijvanich P. Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection. PLoS One 2020;15:e0244112. [PMID: 33382729 DOI: 10.1371/journal.pone.0244112] [Reference Citation Analysis]
63 Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, Enomoto M, Kawada N, Hino M. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. Int J Mol Sci 2020;21:E4517. [PMID: 32630450 DOI: 10.3390/ijms21124517] [Reference Citation Analysis]
64 Mosa AI, AbouHaidar MG, Urbanowicz RA, Tavis JE, Ball JK, Feld JJ. Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. Virol J 2020;17:140. [PMID: 32948191 DOI: 10.1186/s12985-020-01408-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Lee H, Chien RN, Pao LH, Kuo CJ, Huang PH, Chang ML. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study. Cells 2021;10:2934. [PMID: 34831156 DOI: 10.3390/cells10112934] [Reference Citation Analysis]
66 Chang ML, Hu JH, Pao LH, Lin MS, Kuo CJ, Chen SC, Fan CM, Chang MY, Chien RN. Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice. BMC Immunol 2021;22:54. [PMID: 34380427 DOI: 10.1186/s12865-021-00445-5] [Reference Citation Analysis]
67 Fujii H, Kimura H, Hasebe C, Akahane T, Satou T, Kusakabe A, Kojima Y, Kondo M, Marusawa H, Kobashi H, Tsuji K, Ogawa C, Uchida Y, Joko K, Mitsuda A, Kurosaki M, Izumi N. Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. JGH Open. [DOI: 10.1002/jgh3.12749] [Reference Citation Analysis]
68 Tabata K, Prasad V, Paul D, Lee JY, Pham MT, Twu WI, Neufeldt CJ, Cortese M, Cerikan B, Stahl Y, Joecks S, Tran CS, Lüchtenborg C, V'kovski P, Hörmann K, Müller AC, Zitzmann C, Haselmann U, Beneke J, Kaderali L, Erfle H, Thiel V, Lohmann V, Superti-Furga G, Brügger B, Bartenschlager R. Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation. Nat Commun 2021;12:7276. [PMID: 34907161 DOI: 10.1038/s41467-021-27511-1] [Reference Citation Analysis]
69 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Ouoba S, Ouedraogo JCRP, Lingani M, E B, Hussain MRA, Ko K, Nagashima S, Sugiyama A, Akita T, Tinto H, Tanaka J. Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis. BMC Infect Dis 2021;21:1126. [PMID: 34724902 DOI: 10.1186/s12879-021-06817-x] [Reference Citation Analysis]
71 Masalova OV, Lesnova EI, Klimova RR, Momotyuk ED, Kozlov VV, Ivanova AM, Payushina OV, Butorina NN, Zakirova NF, Narovlyansky AN, Pronin AV, Ivanov AV, Kushch AA. Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce Effective Immune Response. Vaccines (Basel). 2020;8. [PMID: 32024236 DOI: 10.3390/vaccines8010062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
72 Maruyama H, Shiina S. Collaterals in portal hypertension: anatomy and clinical relevance. Quant Imaging Med Surg 2021;11:3867-81. [PMID: 34341755 DOI: 10.21037/qims-20-1328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14:497. [DOI: 10.3390/v14030497] [Reference Citation Analysis]
74 Zheng F, Li N, Xu Y, Zhou Y, Li YP. Adaptive mutations promote hepatitis C virus assembly by accelerating core translocation to the endoplasmic reticulum. J Biol Chem 2021;296:100018. [PMID: 33144326 DOI: 10.1074/jbc.RA120.016010] [Reference Citation Analysis]
75 Pramod S, Kheetan M, Ogu I, Alsanani A, Khitan Z. Viral Nephropathies, Adding SARS-CoV-2 to the List. Int J Nephrol Renovasc Dis 2021;14:157-64. [PMID: 34113150 DOI: 10.2147/IJNRD.S303080] [Reference Citation Analysis]
76 Paisi M, Crombag N, Burns L, Bogaerts A, Withers L, Bates L, Crowley D, Witton R, Shawe J. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: A mixed-methods systematic review. Health Expect 2021. [PMID: 34862710 DOI: 10.1111/hex.13400] [Reference Citation Analysis]
77 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
78 Devi P, Punga T, Bergqvist A. Activation of the Ca2+/NFAT Pathway by Assembly of Hepatitis C Virus Core Protein into Nucleocapsid-like Particles. Viruses 2022;14:761. [DOI: 10.3390/v14040761] [Reference Citation Analysis]
79 Giovannoni F, Li Z, Remes-Lenicov F, Dávola ME, Elizalde M, Paletta A, Ashkar AA, Mossman KL, Dugour AV, Figueroa JM, Barquero AA, Ceballos A, Garcia CC, Quintana FJ. AHR signaling is induced by infection with coronaviruses. Nat Commun 2021;12:5148. [PMID: 34446714 DOI: 10.1038/s41467-021-25412-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Shin EC, Han JW, Kang W, Kato T, Kim SJ, Zhong J, Kim S, Park SH, Sung PS, Watashi K, Park JY, Windisch MP, Oh JW, Wakita T, Han KH, Jang SK. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses. Viruses 2020;12:E302. [PMID: 32168867 DOI: 10.3390/v12030302] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Messina V, Onorato L, Di Caprio G, Claar E, Iovinella V, Russo A, Rosato V, Salzillo A, Nevola R, Simeone F, Curcio F, Pisaturo M, Coppola N. Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. Life (Basel) 2020;11:17. [PMID: 33396802 DOI: 10.3390/life11010017] [Reference Citation Analysis]
82 Krag A, Roskams T, Pinzani M, Mueller S. Diagnostic challenges in patients with alcohol-related liver disease. Z Gastroenterol 2022;60:45-57. [PMID: 35042253 DOI: 10.1055/a-1713-4372] [Reference Citation Analysis]
83 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]
84 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
85 Politi J, Guerras JM, Donat M, Belza MJ, Ronda E, Barrio G, Regidor E. Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain. Hepatology 2021. [PMID: 34773281 DOI: 10.1002/hep.32237] [Reference Citation Analysis]
86 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
87 Fu Z, Dong C, Ge Z, Wang C, Zhang Y, Shen C, Li J, Zhu C, Wang Y, Huang P, Yue M. High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis. Front Med (Lausanne) 2021;8:608760. [PMID: 34169081 DOI: 10.3389/fmed.2021.608760] [Reference Citation Analysis]
88 Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, Yang SS, Su WW, Wu JC, Lee TH, Peng CY, Tseng KC, Qin A, Huang YW, Chen PJ. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open 2021;5:929-40. [PMID: 34386602 DOI: 10.1002/jgh3.12613] [Reference Citation Analysis]
89 Alvaro-Meca A, Maté-Cano I, Ryan P, Briz V, Resino S. Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000-2015): A Nationwide Study. J Clin Med 2020;9:E1607. [PMID: 32466412 DOI: 10.3390/jcm9061607] [Reference Citation Analysis]
90 Wiegand J, Berg T. Hepatitis C-committing the world to an eradication of the infection. Hepatobiliary Surg Nutr 2021;10:96-9. [PMID: 33575293 DOI: 10.21037/hbsn.2020.03.26] [Reference Citation Analysis]